Locations:

Image of Note: 3-D Printing in Congenital Heart Disease

3-D replica informs an innovative operation in a deeply cyanosed child

3D heart

By Patcharapong Suntharos, MD, and Hani Najm, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Ethan is a 9-year-old boy with heterotaxy syndrome that was characterized by complex congenital heart disease involving the following:

  • Situs inversus
  • Complete common atrioventricular canal
  • Total anomalous pulmonary venous return (TAPVR)
  • Left superior and inferior vena cavae to the left-sided atrium
  • Two good-sized D-loop ventricles with the aorta arising from the right ventricle remote from the ventricular septal defect
  • Pulmonary atresia with multiple major aortopulmonary collateral arteries (MAPCAs)

As an infant, he underwent TAPVR repair with anastomosis of the pulmonary venous confluence to the right side of the common atrium followed by unifocalization of his MAPCAs to a 12-mm aortic homograft-valved conduit connected to the right ventricle. He later underwent nine cardiac catheterizations, mainly to alleviate significant pulmonary artery branch stenoses and augment pulmonary artery blood flow. Nevertheless, he still had profound cyanosis.

In July 2016, we needed to innovate a procedure to improve oxygen saturation values in this deeply cyanosed child, but standard imaging modalities were inadequate for surgical planning. Building on Cleveland Clinic’s experience developing 3-D-printed heart replicas to plan transcatheter pulmonary valve implantations in patients with congenital defects, we decided to generate a 3-D-printed model of Ethan’s heart to assist our planning.

Using contrast-enhanced MRIs and CTs of his heart, we developed the 3-D-printed model shown above, which allowed us to examine the probability of whether a procedure could improve his oxygen saturations. When the surgeon (co-author Hani Najm, MD) was able to hold the exquisitely detailed heart replica in hand and make an incision in it, the feasibility of our proposed novel procedure was demonstrated.

Advertisement

That procedure was executed in real life exactly as planned on the 3-D replica, and the outcome was excellent. Ethan is now doing very well, with saturation percentages in the low 90s — a level he had never achieved before.

3-D-printed heart replicas are exceptional tools for planning percutaneous and surgical interventions for complex congenital heart defects. Our team looks forward to more opportunities to apply this technology in previously untreatable cases.

Dr. Suntharos is a pediatric and congenital interventional cardiologist, and Dr. Najm is Chair of Pediatric and Congenital Heart Surgery, both at Cleveland Clinic.

Advertisement

Related Articles

human intestines with inset showing gut microbes

TMAO Emerges as a Biomarker for AAA Risk

Elevated levels of the gut microbial metabolite predict prevalence and adverse outcomes in community-based study

physician pointing to a heart model and speaking to a woman

Cardiovascular Implications of Clonal Hematopoiesis of Indeterminate Potential (CHIP)

They generally depend on the mutated gene, clone size and clinical setting

cardiac echo and cardiac CT images side by side

Indexed CTA Measures Sharpen Risk Prediction in Ascending Aortopathy

Large analysis adds to evidence that absolute diameter alone may miss vulnerable patients

operating room during robotic lung transplant surgery

Successful First Case Launches Cleveland Clinic’s Robotic Lung Transplant Program

Procedure places the center among only a handful worldwide to offer the minimally invasive approach

stylized illustration of cholesterol particle floating in bloodstream

Novel siRNA Produces Deep, Durable Reduction in Lp(a)

Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability

converging lines on a graph pointing downward

Oxidized Phospholipids Track Closely With Lp(a) Reductions in Clinical Trial

Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran

sight picture overlaid on DNA double helix

Positive Effects of CRISPR-Cas9 Gene Editing for Dyslipidemia Endure Through 1 Year

Durability findings propel potential one-time treatment approach to phase 1b testing

Doctor examining patient's heart with a stethoscope

New Guideline Calls on Cardiologists to Think Beyond Silos When Managing CKM Syndrome

Practical takeaways for the reality of overlapping cardiovascular, kidney and metabolic disease

Ad